High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

Frank Antony, Cecilia Deantonio, Diego Cotella, Maria Felicia Soluri, Olga Tarasiuk, Francesco Raspagliesi, Fulvio Adorni, Silvano Piazza, Yari Ciani, Claudio Santoro, Paolo Macor, Delia Mezzanzanica, Daniele Sblattero

Research output: Contribution to journalArticle

Abstract

The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95%) and specificity (98%). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.

Original languageEnglish
Article numbere1614856
JournalOncoImmunology
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 2 2019

Fingerprint

Ascitic Fluid
Ovarian Neoplasms
Antibodies
Neoplasm Antigens
Immunoglobulins
Antigens
Antibody Formation
HMGN2 Protein
Neoplasms
Enzyme-Linked Immunosorbent Assay
Neoplasm Antibodies
Protein Array Analysis
Platinum
Gene Library
Ascites
Autoantibodies
Bacteriophages
Early Diagnosis
Proteins
Clone Cells

Keywords

  • ascite
  • biomarker
  • Ovarian cancer
  • protein microarray
  • tumor-associated antigen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Antony, F., Deantonio, C., Cotella, D., Soluri, M. F., Tarasiuk, O., Raspagliesi, F., ... Sblattero, D. (2019). High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. OncoImmunology, 8(9), [e1614856]. https://doi.org/10.1080/2162402X.2019.1614856

High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. / Antony, Frank; Deantonio, Cecilia; Cotella, Diego; Soluri, Maria Felicia; Tarasiuk, Olga; Raspagliesi, Francesco; Adorni, Fulvio; Piazza, Silvano; Ciani, Yari; Santoro, Claudio; Macor, Paolo; Mezzanzanica, Delia; Sblattero, Daniele.

In: OncoImmunology, Vol. 8, No. 9, e1614856, 02.09.2019.

Research output: Contribution to journalArticle

Antony, F, Deantonio, C, Cotella, D, Soluri, MF, Tarasiuk, O, Raspagliesi, F, Adorni, F, Piazza, S, Ciani, Y, Santoro, C, Macor, P, Mezzanzanica, D & Sblattero, D 2019, 'High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids', OncoImmunology, vol. 8, no. 9, e1614856. https://doi.org/10.1080/2162402X.2019.1614856
Antony, Frank ; Deantonio, Cecilia ; Cotella, Diego ; Soluri, Maria Felicia ; Tarasiuk, Olga ; Raspagliesi, Francesco ; Adorni, Fulvio ; Piazza, Silvano ; Ciani, Yari ; Santoro, Claudio ; Macor, Paolo ; Mezzanzanica, Delia ; Sblattero, Daniele. / High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. In: OncoImmunology. 2019 ; Vol. 8, No. 9.
@article{e61a0555d41744f8b2d738d0c8a3d41b,
title = "High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids",
abstract = "The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95{\%}) and specificity (98{\%}). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.",
keywords = "ascite, biomarker, Ovarian cancer, protein microarray, tumor-associated antigen",
author = "Frank Antony and Cecilia Deantonio and Diego Cotella and Soluri, {Maria Felicia} and Olga Tarasiuk and Francesco Raspagliesi and Fulvio Adorni and Silvano Piazza and Yari Ciani and Claudio Santoro and Paolo Macor and Delia Mezzanzanica and Daniele Sblattero",
year = "2019",
month = "9",
day = "2",
doi = "10.1080/2162402X.2019.1614856",
language = "English",
volume = "8",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "9",

}

TY - JOUR

T1 - High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

AU - Antony, Frank

AU - Deantonio, Cecilia

AU - Cotella, Diego

AU - Soluri, Maria Felicia

AU - Tarasiuk, Olga

AU - Raspagliesi, Francesco

AU - Adorni, Fulvio

AU - Piazza, Silvano

AU - Ciani, Yari

AU - Santoro, Claudio

AU - Macor, Paolo

AU - Mezzanzanica, Delia

AU - Sblattero, Daniele

PY - 2019/9/2

Y1 - 2019/9/2

N2 - The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95%) and specificity (98%). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.

AB - The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95%) and specificity (98%). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.

KW - ascite

KW - biomarker

KW - Ovarian cancer

KW - protein microarray

KW - tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=85067045897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067045897&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2019.1614856

DO - 10.1080/2162402X.2019.1614856

M3 - Article

AN - SCOPUS:85067045897

VL - 8

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 9

M1 - e1614856

ER -